Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Agenus reported Phase 2 NEOASIS results at ESMO 2026 showing 83% major pathologic response and 72% pathologic complete response in locally advanced dMMR colon cancer after just six weeks of neoadjuvant BOT+BAL. All 18 patients proceeded to surgery, side effects were mostly mild and manageable, and all patients were alive at a median follow-up of 15 months, with 16 of 18 free of recurrence. NKI investigators are enrolling a dMMR rectal cancer organ-preservation cohort, and Agenus is advancing the short-course approach in MSS colon cancer, which represents about 85% of early-stage colon cancer cases.
Key figures
- Drug Name
- botensilimab (BOT) + balstilimab (BAL)
- Phase Of Trial
- Phase 2
- Mpr rate
- 83%
- Pcr rate
- 72%
- Recurrence free
- 16 of 18
- Patients enrolled
- 18
- Median follow up months
- 15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.